Private Equity Consolidates Orthopedic OEMs: Montagu’s Platform Play in Spinal Fusion Market

Driving the news

Montagu Private Equity is executing a systematic consolidation strategy in the orthopedic OEM space, most recently announcing plans to combine Tyber Medical, Intech and Resolve Surgical Technologies to create a world-leading medical devices supplier focused on the rapidly growing spinal fusion market.

• The spinal fusion devices market was valued at $7.67 billion in 2022 and projected to reach $10.8 billion by 2031.

• Montagu’s platform-building began with acquiring RTI Surgical’s OEM business for $490 million in January 2020.

• The firm added Collagen Solutions to RTI Surgical in October 2024, enhancing biomaterial capabilities.

• This consolidation represents one of the most significant strategic moves in orthopedics since Stryker’s $1.65B Mako Surgical acquisition.

Why it matters

Mid-market PE investors are increasingly recognizing the value-creation potential in building focused medical device manufacturing platforms rather than diversified conglomerates. As a Chief Technology Officer from Woozle’s expert network at a mid-sized spinal implant manufacturer explains, “The consolidation of specialized manufacturers creates significant economies of scale in R&D and regulatory affairs that smaller players cannot match.”

• Reimbursement pressures are driving OEMs to seek integrated solution providers over component suppliers.

• Specialized platforms command premium multiples from strategic acquirers seeking category dominance.

• Biomaterial innovations represent the highest-margin opportunity in the spine sector today.

• Focused platforms enable specialized management teams and clearer exit strategies to strategic buyers.

The big picture

Montagu’s strategic approach reveals a sophisticated understanding of the orthopedic OEM landscape, where operational focus and material science innovation drive outsized returns. The firm is deliberately separating business units with fundamentally different operational models and regulatory pathways, as evidenced by RTI Surgical’s January 2022 spin-off of its Metals business.

• Material science innovations, particularly in biomaterials, command premium pricing while reducing manufacturing complexity.

• The spinal fusion market growth is driven by innovations in surgical techniques and advanced materials.

• Proprietary biomaterial platforms create powerful margin expansion levers for PE investors conducting thematic investment research.

• Successful platforms require early standardization of quality management systems across acquisitions.

Between the lines

Woozle’s primary research and expert surveys suggest Montagu is executing a three-part value creation strategy: operational consolidation, technology specialization, and strategic positioning for eventual sale to a larger strategic buyer. This approach addresses the fundamental challenge in medical device manufacturing roll-ups that a Senior Director of Quality Assurance from Woozle’s network identifies: “Quality system integration represents the single greatest operational challenge, often consuming 12-18 months and significant resources.”

• Successful platforms implement standardized quality systems early, before full operational integration.

• Separating metals from biologics businesses reflects different operational models and regulatory pathways.

• The Collagen Solutions acquisition accelerates development of innovative biomaterials for higher margins.

• Early quality system integration prevents costly remediation that can destroy investment returns.

What’s next

PE investors considering the orthopedic OEM space should evaluate potential platform investments through the lens of material science differentiation, quality system scalability, and strategic buyer alignment. Conducting thorough commercial due diligence with sector specialists can validate consolidation opportunities before committing capital.

• Forward-looking underwriting should model 18-24 months for full quality system integration across acquisitions.

• Successful platforms will likely command 12-15x EBITDA from strategic buyers seeking category dominance.

• Biomaterial innovation represents a key differentiator for premium exit valuations.

• Quick-turn expert calls can validate operational risks before committing to a sector strategy.

Expert perspectives for diligence

When evaluating orthopedic manufacturing platforms, PE investors should engage with Woozle’s vetted network of non-financial experts who can provide critical insights into operational challenges and value creation opportunities:

• Chief Technology Officer (Senior Executive) at a mid-sized spinal implant manufacturer can assess innovation pipelines, regulatory pathways, and R&D efficiency metrics that drive premium valuations. Valuable for deal teams seeking to understand technology differentiation opportunities and emerging product categories that could drive premium valuations.

• VP of Operations (Senior Leadership) at a contract manufacturer for spine and orthopedic OEMs provides critical insights into margin improvement levers, operational scalability, and manufacturing consolidation opportunities. Essential for deal teams evaluating operational synergies and integration timelines in platform strategies.

• Director of Business Development (Commercial Leadership) at a tissue-based implant provider offers perspective on revenue diversification, customer concentration risks, and go-to-market strategies. Helps deal teams validate commercial thesis and identify untapped revenue opportunities in biomaterials.

• Head of Regulatory Affairs (Senior Executive) at a multi-national spine device manufacturer is essential for understanding regulatory risks, time-to-market factors, and compliance requirements that impact valuation. Critical for deal teams assessing regulatory barriers to entry and compliance costs across acquisition targets.

• Senior Director of Quality Assurance (Senior Leadership) at a medical device CDMO specializing in orthopedics provides insight into quality-related risks during platform integration and operational excellence initiatives that protect margins. Helps deal teams identify integration risks and quality system harmonization costs often missed in standard diligence.

The consolidation trend in orthopedic OEMs presents a compelling opportunity for mid-market PE investors who can navigate the operational complexities of medical device manufacturing. Firms that build focused platforms with proprietary biomaterial capabilities and streamlined quality systems will be positioned to capture premium valuations from strategic buyers seeking category dominance.